- ►spendocrinologia.org.pe [PDF] GC Alexander, NL Sehgal, RM Moloney, RS … - Archives of Internal Medicine, 2008 - Am Med Assoc Results The estimated number of patient visits for treated diabetes increased
from 25 million (95% confidence interval [CI], 23 million to 27 million) in 1994
to 36 million (95% CI, 34 million to 38 million) by 2007. The mean number ... Cited by 12 - Related articles - All 6 versions
KE Bainbridge, CC Cowie, KF Rust, JE … - Diabetes Care, 2008 - Am Diabetes Assoc OBJECTIVE—Performance measures are tools for assessing quality of care but may
be influenced by patient factors. We investigated how currently endorsed
performance measures for glycemic control in diabetes may be influenced by ... Cited by 1 - Related articles - All 5 versions
RK Campbell - Journal of the American Pharmacists Association, 2009 - Am Pharmacists Assoc The prevalence of type 2 diabetes has increased alarmingly ... At A Glance
Synopsis: Recent insight into key pathogenic and pathophysiologic mechanisms of
type 2 diabetes, in- cluding incretin hormone impairments, has led to new ... Cited by 1 - Related articles - All 2 versions
ME Cobble - American Journal of Therapeutics, 2009 - journals.lww.com With the exception of insulin, all diabetes medications have limited
glucose-lowering capacity. Therefore, as type 2 diabetes progresses, insulin is
often needed to achieve near-normal glycemic targets and avoid ... Cited by 1 - Related articles - All 2 versions
AM Albisser, R Alejandro, M Sperlich, B Ed, C … - Journal of Diabetes Science and Technology, 2009 - journalofdst.org Background: Satisfactory glycemic control, meeting American Diabetes Association
recommendations, is often accompanied by unsatisfactory hypoglycemia. The
converse is also true. We hypothesize that this diabetes treatment dilemma ... Cited by 1 - Related articles - View as HTML - All 2 versions
RE Pratley - Expert Opin. Pharmacother., 2009 - informahealthcare.com Background: Alogliptin is a potent, highly selective dipeptidyl peptidase-4
inhibitor now undergoing clinical testing to support a new drug application for
the treatment of type 2 diabetes. Objective: To provide an overview of the ... Cited by 1 - Related articles - All 7 versions
JI Lee, HS Kwon, SJ Oh, JM Lee, SA Chang, … - synapse.koreamed.org Cardiovascular disease (CVD) is the major cause of mortality in type 2 diabetes
mellitus. CVD is a clinical manifestation of atherosclerosis, a chronic and
progressive inflammatory disease characterized by a long asymptomatic ... Related articles - Cached - All 2 versions
- ►diabetesjournals.org J Fradkin, GP Rodgers - Diabetes care, 2008 - Am Diabetes Assoc The new data presented in this issue (1) estimating the 2007 economic cost of
diabetes in the US at $174 billion are sobering. One in five health care dollars
is spent caring for someone with diabetes, and one in ten dollars spent on ... Related articles - BL Direct - All 6 versions
